



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: February 26, 2009  (use as many sheets as necessary)		<b>Application Number</b>	10/622,470		
		<b>Filing Date</b>	7/21/2003		
		<b>First Named Inventor</b>	Debbi DRANE		
		<b>Art Unit</b>	1648		
		<b>Examiner Name</b>	Bao Q. Li		
<b>Sheet</b>	1	<b>of</b>	7	<b>Attorney Docket Number</b>	017227-0190

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1				
	A2	US 5,897,873	04-13-1999	Popescu	
	A3	US 2003/0118635 A1	06-26-2003	Dalsgaard et al.	
	A4	US 2003/0139364 A1	07-24-2003	Kreig et al.	
	A5	US 2003/0191079 A1	10-09-2003	Kreig et al.	
	A6	US 2004/0038922 A1	02-26-2004	Haensler et al.	
	A7	US 2004/0106568 A1	06-03-2004	Krieg et al.	
	A8	US 2004/0247662 A1	12-09-2004	Dow et al.	
	A9	US 2004/0266719 A1	12-30-2004	McCluskie et al.	
	A10	US 2005/0013812 A1	01-20-2005	Dow et al.	
	A11	US 2005/0031638 A1	02-10-2005	Dalemans et al.	
	A12	US 2005/0037985 A1	02-17-2005	Krieg et al.	
	A13	US 2005/0079152 A1	04-14-2005	Bot et al.	
	A14	US 2005/0101554 A1	05-12-2005	Krieg et al.	
	A15	US 2005/0119273 A1	06-02-2005	Lipford et al.	
	A16	US 2005/0130911 A1	06-19-2005	Uhlmann et al.	
	A17	US 2005/0215501 A1	09-29-2005	Lipford et al.	
	A18	US 2006/0003962 A1	01-05-2006	Ahluwalia et al.	
	A19	US 2006/0019923 A1	01-26-2006	Davis et al.	
	A20	US 2006/0058251 A1	03-16-2006	Krieg et al.	
	A21	US 2006/0172966 A1	08-03-2006	Lipford et al.	
	A22	US 2006/0188913 A1	08-24-2006	Krieg et al.	
	A23	US 2006/0229271 A1	10-12-2006	Krieg et al.	
	A24	US 2006/0246035 A1	11-02-2006	Ahluwalia et al.	
	A25	US 2007/0232622 A1	10-04-2007	Lipford et al.	
	A26	US 4,578,269	03-25-1986	Morein	
	A27	US 4,981,684	01-01-1991	MacKenzie et al.	
	A28	US 5,178,860	01-12-1993	MacKenzie et al.	
	A29	US 5,284,656	02-08-1994	Platz et al.	
	A30	US 5,451,569	09-19-1995	Wong et al.	
	A31	US 5,679,354	10-21-1997	Morein et al.	
	A32	US 6,558,670 B1	05-06-2003	Friede et al.	
	A33	US 6,610,308 B1	08-26-2003	Haensler	
	A34	US 6,027,732	02-22-2000	Morein et al.	
	A35	US 6,339,068 B1	01-15-2002	Krieg et al.	
	A36	US 5,057,540	10-15-1991	Kensil et al.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: February 26, 2009  <i>(use as many sheets as necessary)</i>				Application Number	10/622,470
				Filing Date	7/21/2003
				First Named Inventor	Debbi DRANE
				Art Unit	1648
				Examiner Name	Bao Q. Li
Sheet	2	of	7	Attorney Docket Number	017227-0190

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A37	US 5,273,965	12-28-1993	Kensil et al.	
	A38	US 5,443,829	08-22-1995	Kensil et al.	
	A39	US 5,583,112	12-10-1996	Kensil et al.	
	A40	US 5,650,398	07-22-1997	Kensil et al.	
	A41	US 5,977,081	11-02-1999	Marciani	
	A42	US 6,080,725	06-27-2000	Marciani	
	A43	US 6,231,859 B1	05-15-2001	Kensil	
	A44	US 7,049,302 B1	05-23-2006	Kensil	
	A45				

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	A46	EP 0 109 942 B1	03-06-1991	Morein, Bror		
	A47	EP 0 180 564 B1	05-07-1986	Morein, Bror		
	A48	WO 98/22135 A1	05-28-1998	Astra Aktiebolag		
	A49	WO 98/36772 A1	08-27-1998	CSL Limited		
	A50	EP 0 231 039 B1	01-08-1992	Nederlanden Staat		
	A51	WO 00/09159 A1	02-24-2000	Aquila Biopharmaceuticals		
	A52	WO 00/15256 A2	03-23-2000	Pasteur Merieux Serums		
	A53	WO 00/62800 A2	10-26-2000	Smithkline Beecham Biol.		
	A54	WO 00/67787 A2	11-16-2000	Immune Response Corp.		
	A55	WO 01/35991 A2	05-25-2001	Dynavax Tech. Corp.		
	A56	WO 02/28428 A2	04-11-2002	Aventis Pasteur		
	A57	WO 02/32450 A2	04-25-2002	Smithkline Beecham Biol.		
	A58	WO 05/004910 A2	01-20-2005	Intercell AG		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: February 26, 2009  <i>(use as many sheets as necessary)</i>				Application Number	10/622,470
				Filing Date	7/21/2003
				First Named Inventor	Debbi DRANE
				Art Unit	1648
				Examiner Name	Bao Q. Li
Sheet	3	of	7	Attorney Docket Number	017227-0190

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A59	WO 90/03184 A1	04-05-1990	Morein, Bror et al.		
	A60	WO 00/41720 A1	07-20-2000	CSL Limited		
	A61	WO 01/37879 A1	05-31-2001	Nanocarrier Co. Ltd.		
	A62	WO 04/039950 A2	05-13-2004	Chiron Corporation		
	A63	WO 01/15727 A2	03-08-2001	Aquila Biopharmaceuticals Inc.		
	A64	WO 01/51083 A2	07-19-2001	Aquila Biopharmaceuticals Inc.		
	A65	WO 99/61056 A2	12-02-1999	Loeb Health Research Inst.		
	A66	WO 95/09179 A1	04-06-1995	Seed Capital Investment B.V.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A67	AL-SHAKHSHIR et al., 1994. Effect of Protein Adsorption on the Surface Charge Characteristics of Aluminum-Containing Adjuvants. Vaccine. Vol. 12(5); pp. 472-474	
	A68	BARR et al., 1996. ISCOMs (immunostimulating complexes): The first decade, Immunology and Cell Biology, vol. 74, pp. 8-25	
	A69	CALLAHAN et al., "The Importance of Surface Charge in the Optimization of Antigen-Adjuvant Interactions", Pharmaceutical Res., vol. 8:7, (1991) pp.851-858	
	A70	COX et al., "Adjuvants-a classification and review of their modes of action", Vaccine 15:3, pp. 248-256, 1997	
	A71	COX et al., "Advances in Adjuvant Technology and Application" in Animal Parasite Control Utilizing Biotechnology" Chpt. 4, Editor Yong, W.K CRC Press, 1992	
	A72	COX et al., "Prospects for the Development of New Vaccine Adjuvants", BioDrugs 12:6, pp. 439-453, 1999	
	A73	RIMMELZWAAN et al., "A Novel Generation of Viral Vaccines Based on the ISCOM Matrix" (1995), pp. 543-558	
	A74	EDWARDS et al., "Design of a Candidate Recombinant Therapeutic Vaccine for Cervical Cancer", Recent Research Devel. In Biotech. And Bioeng., pp. 343-356, 1998	
	A75	ELLIOTT et al., "Peptide based Cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and Problems", Vaccine vol. 17, pp. 2009-2019, 1999	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: February 26, 2009 (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/622,470
		Filing Date	7/21/2003
		First Named Inventor	Debbi DRANE
		Art Unit	1648
		Examiner Name	Bao Q. Li
Sheet	4	of	7
		Attorney Docket Number	017227-0190

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A76	FRIEDE et al., "Induction of Immune Response Against a Short Synthetic Peptide Antigen Coupled . . . Containing Monophosphoryl Lip A," Molecular Immun., vol. 30:6, pp.539-547, 1993	
	A77	GUPTA et al., "Aluminum compounds as vaccine adjuvants", Advanced Drug Delivery Reviews 32 (1998) 155—172.	
	A78	LIPFORD et al., "Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells", Vaccine 1994, Vol. 12, No. 1, pp. 73-80.	
	A79	MOREIN et al., "Immunostimulating Complex (ISCOM) in Vaccines: Recent Trends and Progress", pp. 153-161, 1989	
	A80	NAKANISHI et al., "Positively Charged Liposome Functions...Immune Responses to Soluble Proteins", Biochemical and Biophysical Res. Communications 240, pp. 793-797, 1997	
	A81	SEEBER et al. 1991. Predicting the Adsorption of Proteins of Aluminum-Containing Adjuvants. Vaccine. Vol. 9, pp. 201-203.	
	A82	TALSMA et al., "Liposomes as Drug Delivery Systems, Part 1: Preparation", BioPharm, pp. 36-47, 1992.	
	A83	COULTER et al., "Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms™) and oil-in-water vaccines," Vaccine, 1997, pp. 1243-1253, Vol. 16, No. 11/12, Elsevier Science Ltd., Great Britain	
	A84	DASS et al., Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J Cancer Res Clin Oncol. 2002 Apr; 128(4): 177-81.	
	A85	EVANS et al., The use of ISCOMATRIX adjuvant for delivery of CpG 7909. July 2004 Meeting. Poster and Abstract.	
	A86	GOUTTEFANGEAS et al., Problem solving for tumor immunotherapy. Nat Biotechnol. 2000 May; 18(5):491-2.	
	A87	GREGORIADIS et al. (Eds.), Vaccine Design, The Role of Cytokine Networks, 1996, TABLE OF CONTENTS ONLY, Plenum Press	
	A88	GROSSMANN et al., Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother. 2001 May-Jun; 24(3):237-41.	
	A89	HARTMANN et al., "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells," Proc. Natl. Acad. Sci. USA, August 1999, pp. 9305-9310, Vol. 96	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: February 26, 2009  <i>(use as many sheets as necessary)</i>				Application Number	10/622,470
				Filing Date	7/21/2003
				First Named Inventor	Debbi DRANE
				Art Unit	1648
				Examiner Name	Bao Q. Li
Sheet	5	of	7	Attorney Docket Number	017227-0190

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A90	LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept 7; 45(7):333A.			
	A91	O'HAGAN et al., Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord. 2001 Nov; 1(3):273-86.			
	A92	SINGH et al., Recent advances in vaccine adjuvants. Pharm Res. 2002 Jun; 19(6):715-28.			
	A93	SINGH et al., Recent advances in veterinary vaccine adjuvants. Int J Parasitol. 2003 May; 33(5-6):469-78.			
	A94	BOMFORD et al., 1992, "Adjuvanticity and ISCOM Formation by Structurally Diverse Saponins," Vaccine 10(9):572-7.			
	A95	BOMFORD, 1982, "Studies on the Cellular Site of Action of the Adjuvant Activity of Saponin for Sheep Erythrocytes," Int. Arch. Allergy Appl. Immunol. 67(2):127-31.			
	A96	CAMPBELL et al., 1992, "Saponin," Res. Immunol. 143(5):526-30; discussion 577-8.			
	A97	COUGHLIN et al., 1995, Adjuvant Activity of QS-21 for Experimental E. Coli 018 Polysaccharide Vaccines," Vaccine 13(1); 17-21			
	A98	DALSGAARD, 1974, "Saponin Adjuvants. 3. Isolation of a Substance from Quillaja Saponaria Molina with Adjuvant Activity in Food-and-Mouth Disease Vaccines," Arch. Gesamte. Virusforsch.. 44(3):243-54			
	A99	ESTRADA et al., 1998, "Adjuvant Action of Chenopodium Quinoa Saponins on the Induction of Antibody Responses to Intragastric and Intranasal Administered Antigens in Mice", Comp. Immunol. Microbiol. Infect. Dis. 21(3):225-36			
	A100	HANCOCK et al, 1995, "Formulation of the Purified Fusion Protein of Respiratory Syncytial Virus with the Saponin QS-21 Induces Protective Immune Responses in Balb/c Mice that are similar to those generated by Experimental Infection," Vaccine 13(4):391-400.			
	A101	HIGUCHI et al., 1987, "Structure of Desacylsaponins Obtained from the Bark of Quillaja Saponaria," Phytochemistry 26:229-35			
	A102	KENSIL et al., 1991, "Separation and Characterization of Saponins with Adjuvant Activity from Quillaja Saponaria Molina Cortex," J. Immunol. 146(2):431-7			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/622,470
Date Submitted: February 26, 2009		<b>Filing Date</b>	7/21/2003
(use as many sheets as necessary)		<b>First Named Inventor</b>	Debbi DRANE
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Bao Q. Li
<b>Sheet</b>	6	<b>Attorney Docket Number</b>	017227-0190
	of		7

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A103	SOLTYSIK et al., 1993, "Adjuvant Activity of QS-21 Isomers," Ann. N.Y. Acad. Sci. 690:392-5	
	A104	KENSIL et al., 1995, "Structural and Immunological Characterization of the Vaccine adjuvant QS-21," Vaccine Design: The Subunit and Adjuvant Approach, Powell and Nuwman eds., Plenum Press, New York	
	A105	KERSTEN et al., "Incorporation of the Major Outer Membrane Protein of Neisseria Gonorrhoeae in Saponin-Lipid Complexes (Isocomes); Chemical Analysis, Some Structural Features, and Comparison of Their Immunogenicity with Three Other Antigen Delivery Systems," Infect. Immun. 56(2):432-8.	
	A106	KERSTEN et al., "On the Structure of Immune-Stimulating Saponin-Lipid Complexes (iscoms)", Biochimica et Biophysica Acta, 1062 (1991) 165-171.	
	A107	LACAILLE-DUBOIS et al., 1996, "A Review of the Biological and Pharmacological Activities of Saponins," Phytomedicine Vol. 2, 363-386.	
	A108	LIVINGSTON et al., 1994, "Phase I Trial of Immunological Adjuvant QS-21 with a GM2 Ganglioside-Keyhole Limpet Haemocyanin Conjugate Vaccine in Patients with Malignant Melanoma," Vaccine 12(14):1275-80.	
	A109	MA et al., "Impact of the Saponin Adjuvant QS-21 and Aluminum Hydroxide on the Immunogenicity of Recombinant OspA and OspB of Borrelia burgdorferi," Vaccine 12(10):925	
	A110	NEWMAN et al., 1992, "Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses," J. Immunol. 148(8):2357-62	
	A111	SOLTYSIK et al., 1995, "Structure/function Studies of QS-21 Adjuvant: Assessment of Triterpene Aldehyde and Glucuronic Acid Roles in Adjuvant Function," Vaccine 13(15):1403-10	
	A112	WHITE et al., 1991, "A Purified Saponin Acts as an Adjuvant for a T-independent Antigen," Immunobiology of Proteins and Peptides, Vol. VI (Atassi ed.), Plenum Press, New York, 207-210.	
	A113	WU et al., 1992, "Saponin Adjuvant Enhancement of Antigen-Specific Immune Responses to an Experimental HIV-I Vaccine," J. Immunol. 148(5):1519-25	
	A114	WU et al., 1994, "Accessory Cell Requirements for Saponin Adjuvant-Induced Class I MHC Antigen-Restricted Cytotoxic T-Lymphocytes," Cell. Immunol. 154(a):393-406	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: February 26, 2009  <i>(use as many sheets as necessary)</i>				Application Number	10/622,470
				Filing Date	7/21/2003
				First Named Inventor	Debbi DRANE
				Art Unit	1648
				Examiner Name	Bao Q. Li
Sheet	7	of	7	Attorney Docket Number	017227-0190

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	B1	US 2006/0287263	12-21-2006	Davis et al.	
	B2	US 2006/0210555 A1	09-21-2006	Kensil et al.	
	B3	US 2009/0017021 A1	01-15-2009	Davis et al.	
	B4	6,352,697 B1	03-05-2002	Cox et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			
	B5	09/506,011	02-17-2000	Cox et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	B6	WO 2007/026190 A2	03-08-2007	CSL Limited		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.